Clinical Characteristics and Outcomes of Coronary Heart Disease (IMPROVE)

April 14, 2025 updated by: Xiang Xie, Xinjiang Medical University

Clinical Characteristics and Outcomes of Coronary Heart Disease: a Prospective Cohort Study

This study evaluated and compared the prognostic value of different Baseline data and clinical variables to develop predictive model in patients with CHD.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

20000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Xinjiang
      • Ürümqi, Xinjiang, China, 630000
        • The First Affiliated Hospital of Xinjiang Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients with coronary heart disease hospitalized at the First Affiliated Hospital of Xinjiang Medical University.

Description

Inclusion Criteria:

  1. Patients diagnosed with Coronary Heart Disease (CHD) admitted to the First Affiliated Hospital of Xinjiang Medical University.
  2. The diagnosis is based on clinical assessments, including symptomatic evaluation, electrocardiographic findings, and coronary angiography.

Exclusion Criteria:

We excluded patients who had serious heart failure, malignant tumor，rheumatic heart disease, valvular heart disease, congenital heart disease, pulmonary heart disease and serious dysfunction of the liver or kidney.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
2
Drug: Drug:Standard therapy
Percutaneous coronary Intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Death （All-cause mortality、Cardiac mortality ）
Time Frame: 5 years of follow-up deaths occurred during this period
5 years of follow-up deaths occurred during this period

Secondary Outcome Measures

Outcome Measure
Time Frame
Major adverse cardiovascular events
Time Frame: 5 years of follow-up deaths occurred during this period
5 years of follow-up deaths occurred during this period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Xinjiang Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2020

Primary Completion (Actual)

January 31, 2022

Study Completion (Actual)

April 30, 2022

Study Registration Dates

First Submitted

March 22, 2024

First Submitted That Met QC Criteria

March 22, 2024

First Posted (Actual)

March 28, 2024

Study Record Updates

Last Update Posted (Actual)

April 17, 2025

Last Update Submitted That Met QC Criteria

April 14, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • xx20190901

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Heart Disease

Clinical Trials on Drug:Standard therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe